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Abstract
It is recognised that some mutated cancer genes contribute to the development of many cancer
types whilst others are cancer-type specific. Amongst genes that affect multiple cancer classes,
mutations are usually similar in the different cancer types. Here, however, we observed exquisite
tumour-type specificity of different histone 3.3 driver mutations. In 73/77 (95%) cases of
chondroblastoma we found K36M mutations predominantly in H3F3B, which is one of two genes
encoding histone 3.3. By contrast, 92% (49/53) of giant cell tumours of bone harboured histone
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3.3 variants exclusively in H3F3A, which were G34W or, in one case, G34L. The mutations were
restricted to the stromal cell population and not detected in osteoclasts or their precursors. In the
context of previously reported H3F3A K27M and G34R/V mutations of childhood brain tumours,
a remarkable picture of tumour-type specificity of histone 3.3 mutations emerges, indicating
distinct functions of histone 3.3 residues, mutations and genes.
Chondroblastoma is a cartilaginous tumour presenting in childhood to early adulthood which
arises in active growth plates, most commonly of long bones1. Although locally destructive
and prone to recurrence, it is considered a benign tumour which rarely metastasises1. The
biology of chondroblastoma is not understood, including its relation to other tumours sited
in the epiphysis, such as giant cell tumour of bone.
Using massively parallel sequencing, we sequenced the complete genomes of six
chondroblastomas and normal DNAs from the same individuals (Supplementary Table 1).
Overall, we identified a relatively low somatic mutation burden, comprising between 542 –
668 substitutions (0.2 / megabase) and 15-25 indels (0.006 / megabase) per genome (Table
1; Supplementary Table 2). The predominant substitution class was C to T, which showed
enrichment at CpG dinucleotides. Copy number and rearrangement analysis showed that the
tumours were overall diploid with a paucity of structural changes (Table 1; Supplementary
Figure 1).
A striking observation was that all six chondroblastomas harboured recurrent somatic
mutations in one of two genes, H3F3A or H3F3B, encoding the replication-independent
histone 3.3. H3F3A and H3F3B reside on chromosomes 1 and 17, respectively. They have
different exonic and intronic DNA sequences, but both encode histone 3.3 proteins of
identical amino acid sequence2,3. Cancer driver mutations have previously been identified in
H3F3A, but not in H3F3B. All six chondroblastomas carried K36M histone 3.3 mutations,
five were in H3F3B and one in H3F3A. No other putative driver variants were identified.
We extended the investigation of H3F3A and H3F3B to an additional 71 chondroblastomas
and, in total, found histone 3.3 mutations in 73/77 (95%). All 73 variants were K36M, with
68 presenting in H3F3B and five in H3F3A (Figure 1; Table 2).
We screened seven additional types of bone and cartilage tumours for the presence of
H3F3A or H3F3B mutations (Table 2). In giant cell tumour of bone we found mutations in
49/53 (92%) cases. All variants were in H3F3A encoding changes at glycine 34; 48 were
G34W and one was G34L (Figure 1; Table 2).
In other bone and cartilage tumours, we found a low prevalence of histone 3.3 mutations
(Table 2). Two osteosarcomas (2%; 2/103) harboured G34R variants, one in H3F3A and one
in H3F3B. One (1%; 1/75) conventional chondrosarcoma had an H3F3A K36M mutation.
We identified one clear cell chondrosarcoma (7%; 1/15) with an H3F3B K36M mutation.
No histone 3.3 variants were found in chondromyxoid fibroma (n=43), chordoma (n=25) or
soft tissue/synovial chondroma (n=7). To search for mutations of other histone 3 genes that
are closely related, but not identical, to H3F3A and H3F3B, we analysed whole exome or
genome sequence of 49/75 chondrosarcoma and of all 103 osteosarcoma cases included in
this study. One osteosarcoma harboured a somatic variant of HIST1H3H of unknown
significance (G12R). Unlike in some childhood brain tumours, we did not identify H3F3A
or HIST1H3H K27M mutations, nor did we observe an association of histone 3.3 variants
with TP53 mutations4-9.
Giant cell tumour of bone, and to a lesser extent chondroblastoma, contains cells of the
osteoclast lineage in addition to stromal cells. In giant cell tumour of bone there has been
some dispute as to which cell type is neoplastic10. Consequently we separated the stromal
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compartment (CD51-/CD61-/CD14-) from osteoclasts (CD51+/CD61+) and osteoclast
precursors (CD14+) in both giant cell tumour of bone and chondroblastoma harbouring
histone 3.3 mutations. The presence of mutations demonstrates that the neoplastic
component of these tumours is represented by stromal cells and not cells of the osteoclast
lineage (Table 3). It is possible that histone 3.3 mutations directly lead to osteoclast
recruitment, for example through alteration of expression of essential osteoclast signals such
as RANK ligand or colony stimulating factor 1.
Taken together, our findings reveal histone 3.3 mutations in five classes of bone and
cartilage neoplasms with an exceptionally high prevalence in chondroblastoma and giant cell
tumours of bone and a low frequency in osteosarcoma, conventional chondrosarcoma and
clear cell chondrosarcoma. Recurrent somatic histone 3.3 mutations have previously been
described in paediatric brain tumours4-9, including up to 60% of diffuse intrinsic pontine
glioma8. Otherwise, histone 3.3 mutations appear to be exceedingly rare. Amongst 1.14
million coding mutations from 885,000 tumours recorded in the Catalogue of Somatic
Mutations in Cancer (COSMIC) 11, there is one mutation at a histone 3.3 hotspot, a K36R
variant found in a urinary tract tumour. Therefore, histone 3.3 driver mutations appear to be
markedly enriched in glial tumours and a subset of primary skeletal neoplasms.
We observed quite remarkable specificity of histone 3.3 mutations for different histogenetic
tumour types, both with respect to which codon is mutated and what amino acid is newly
substituted (Figure 1). Histone 3.3 K36M mutations were confined to a subset of cartilage
tumours, namely chondroblastoma and chondrosarcoma, whilst glycine 34 was mutated in
tumours of osteoblast lineage, osteosarcoma and giant cell tumour of bone. Lysine 27, which
is the principal methylation site mutated in paediatric brain tumours, is not affected in bone
and cartilaginous tumours. Likewise, lysine 36 which is the principal methylation site
mutated in chondroblastoma, is not mutated in bone or brain tumours. At glycine 34, which
is mutated in both bone and paediatric brain tumours, mutations to valine or arginine are
found in brain tumours while mutations to tryptophan are confined to giant cell tumours of
bone. Thus, there is a dramatic association of each tumour type with a specific histone 3.3
mutation. The most likely explanation of this phenomenon is that particular histone 3.3
mutations confer differential growth advantage on specific cell types. Although, in principle,
different mutational processes in different neoplasms could account for the tumour-
specificity of the histone 3.3 mutations, this appears unlikely as the overall patterns of
somatic substitutions are similar in these tumour types.
An association of mutations of specific codons with different cancer types has been reported
in other cancer genes. In NRAS, for example, Q61 is more frequently mutated in melanoma
than the other two mutation hotspots, G12 and G13, which are predominantly mutated in
leukaemias12. Other examples include BRAF and TP53 in which certain mutation hotspots
demonstrate a bias for specific tumour types11,13. However, the mutual exclusivity of
histone 3.3 mutations between brain tumours, giant cell tumour of bone and
chondroblastoma, that we report here, is unprecedented.
To our knowledge, this is also the first description of somatic driver mutations presenting in
different genes encoding an identical protein. The reasons for this phenomenon remain
uncertain. However, the clear preferences for H3F3A mutations in tumours of osteoblastic
lineage and glial cells, and for H3F3B mutations in cartilaginous neoplasms, indicate that
the two genes are unlikely to be redundant with respect to function. One possibility is that
differential gene expression may account for the selective pattern of mutation in different
tumour types. We assessed expression levels of H3F3A and H3F3B in ten cases each of
giant cell tumour of bone (H3F3A G34W mutant) and chondroblastoma (H3F3B K36M
mutant) and did not find significant differences in gene expression between the tumour
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types. Our findings do not exclude the possibility that temporal differences underlie the
tumour specificity of H3F3A and H3F3B, especially as differential expression patterns of
the two genes have been observed during embryonic and post-natal development in normal
murine and human tissues14,15.
The accumulation of histone 3.3 mutations in paediatric brain tumours has sparked a number
of functional investigations seeking to evaluate the function of key regulatory sites, such as
critical lysines which are targets of post-translational methylation. Histone 3.3 lysine to
methionine mutations, including K9M, K27M, and K36M, were found to reduce
methylation of these residues through inhibition of SET domain-containing enzymes16.
Interestingly, G34R and G34V substitutions decreased methylation at K3616. In addition,
expression profiling of histone 3.3 K27M mutant cell lines demonstrated genome-wide
changes of gene expression which appeared to disrupt multiple cancer pathways17. Amongst
these, MYCN upregulation has been identified as a potential downstream target of histone
3.3 mutation in a gene expression study of a mutant H3F3A G34V glioma cell line18.
Collectively, these studies begin to provide a mechanistic insight into histone 3.3 mutations
and corroborate the genomic evidence that the recurrent somatic mutations of histone 3.3 at
regulatory residues K27, G34, and K36 are dominant driver events.
Our study reveals novel histone 3.3 mutations in a variety of bone and cartilage tumours.
Given the exceptionally high prevalence of mutually exclusive histone 3.3 mutations in
chondroblastoma and giant cell tumour of bone, it seems likely these tumours are defined by
distinct histone 3.3 mutations, which may have immediate diagnostic utility, especially in
morphologically ambiguous cases. The unprecedented tumour-type specificity of histone 3.3
mutations indicates fundamental differences in the function of histone 3.3 amino acid
residues in tumour development that may pertain to normal differentiation of bone and
cartilage cells. It is conceivable that chondroblastoma and giant cell tumour of bone derive
from a common precursor cell, the differentiation of which is determined by specific histone
3.3 variants. A future challenge will be to investigate the functional repercussions of these




Informed consent was obtained from all subjects and ethical approval obtained from
Cambridgeshire 2 Research Ethics Service (reference 09/H0308/165). Collection and use of
patient samples were approved by the appropriate institutional review board (IRB) of each
Institution.
Whole genome sequencing
DNA was extracted from 6 chondroblastomas as well as matched normal tissue derived from
the same individuals. Short insert 500bp library construction, flowcell preparation and
cluster generation was performed according to the Illumina no-PCR library protocol. 100
base paired-end sequencing was performed on Illumina Hiseq 2000 analysers, as described
in the Illumina Genome Analyzer operating manual. Reads were aligned to the reference
human genome (NCBI37) by using BWA on default settings19. Reads which were
unmapped or PCR-derived duplicates were excluded from the analysis. The average
coverage of tumours was 40X and of normal DNA 30X.
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The CaVEMan (cancer variants through expectation maximization) algorithm was used to
call single nucleotide substitutions20. To call insertions and deletions, we used split-read
mapping implemented as a modification of the Pindel algorithm21. To call rearrangements
we applied the BRASS (breakpoint via assembly) algorithm, which identifies
rearrangements by grouping discordant read pairs that point to the same breakpoint event22.
Post-processing filters were applied to the output to improve specificity. Mutations were
annotated to Ensembl version 58.
Variant validation
Variants were subjected to validation by manual inspection, and artefacts excluded from the
data set. All ambiguous variants (141 substitutions; 24 indels) as well as randomly selected
indels (n=25; 12%) and substitutions (n=339; 8%) were experimentally validated. To this
end, DNA of the tumours and normal tissue from same individuals was amplified by PCR
(primer sequences available on request) targeting the variant location. Resulting PCR
amplicons were sequenced on an Illumina MiSeq (read length 150 base pairs) to a median
depth of 7400X. The overall specificity for the catalogue of substitutions and indels was thus
determined to be at least 95%. All histone 3.3 variants detected in whole genomes were
separately validated by capillary sequencing, as described below.
Extension study
185 tumours were screened by capillary sequencing (primers available on request) for the
presence of H3F3A and H3F3B variants between codons 29 and 63: 70 chondroblastoma, 43
chondromyxoid fibroma; 51 giant cell tumours of bone; 14 clear cell chondrosarcoma; 7 soft
tissue / synovial chondromas. DNA from these 185 tumours was extracted from formalin-
fixed paraffin-embedded tissue and from fresh frozen tissue in 22 cases as well, along with
normal tissue from the same individuals.
Using DNA from fresh frozen tissue, we used massively parallel sequencing (whole
genome, whole exome sequencing or targeted capture of histone 3.3 genes), as previously
described20,22, to screen H3F3A and H3F3B for the presence of mutations in 213 tumours:
103 osteosarcoma, 75 chondrosarcoma, 25 chordoma, 2 cases of giant cell tumours of bone,
1 case of clear cell chondrosarcoma, and 1 case of chondroblastoma. Mutations found in
histone 3.3 genes or related genes were validated by capillary sequencing or massively
parallel sequencing.
TP53 screen
Giant cell tumour of bone cases (47/53) were screened for TP53 mutations. Libraries of
targeted 120bp fragments were generated by Fluidigm, according to the manufacturer’s
instructions, and sequenced by Ion Torrent One Touch version 2 and Personal Genome
Machine with 316 chip, according to the manufacturer’s instructions with minor
modifications. Reads were analysed by manual inspection and by samtools mpileup
incorporated into custom software.
Detection of copy number variation
Copy number data were derived from whole genome reads using the ASCAT (version 2.2)
algorithm23 and validated by SNP6.0 in 5/6 cases. Variant zygosity was derived by
determining mutation copy number, as previously described24.
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Fresh tissue from 1 case of giant cell tumour of bone (radius) and 1 case of chondroblastoma
(femur) was obtained at time of surgery from the Royal National Orthopaedic Hospital,
Brockley Hill, Stanmore, UK. The tumours were processed as previously described25 with
some modifications. Following collagenase digestion for 2 hours, the cells were cultured for
14 days, and on reaching confluence were passaged twice during that period to enrich for the
trypsin-sensitive stromal cell population. The trypsin-resistant large multinucleated
osteoclasts, and a smaller population of mononuclear cells persisted in the flasks following
the first treatment with trypsin, but new osteoclasts developed when the cells were replated.
Following the second passage the cells were incubated with the mouse anti-human
monoclonal (IgG1) antibody 23C6 (ab34226; Abcam, Cambridge, UK) directed against
CD51 and CD61, the vitronectin receptor (VNR) expressed by osteoclasts26,27, followed by
rat anti-mouse IgG1 microbeads (Miltenyi Biotech, Surrey, UK). This was followed by
incubation with mouse anti-human monoclonal (IgG2a) CD14 microbeads (Miltenyi
Biotech, UK) according to the manufacturers’ recommendations for the purpose of selecting
osteoclast precursors. The cells were sorted manually using a Minimax magnetic cell
separator (Miltenyi Biotech, UK) according to the manufacturer’s instructions. Each
fraction, the CD51/61/CD14-negative, as well as the CD51/CD61/CD14-positive fraction of
each tumour, was sorted three times. Using RT-PCR on RNA extracted from paraffin-
embedded tissue (RNeasy Minikit, Qiagen, UK) we confirmed that cells from the stromal
compartment express genes specific to stromal cells (COL1A1) and do not express markers
of osteoclasts and their precursors (CD45, ACP5 and CD14). DNA was extracted from the
resulting cell populations and screened for H3F3A and H3F3B mutations by massively
parallel sequencing.
Gene expression analyses
Total RNA was isolated from paraffin embedded tissue of 10 cases of giant cell tumour of
bone and 10 cases of chondroblastoma and was reverse transcribed using Superscript III
First-Strand Synthesis kit (Invitrogen Ltd/Life Technologies Ltd, Paisley, Scotland, UK).
Specific gene primers were designed with Primer 3 and real-time PCR was performed with
SsoFast EvaGreensupermix from Biorad (Hemel Hempstead, Hertfordshire, UK; primer
sequences available upon request). The average of two independent analyses for each target
gene and sample was calculated and was normalised to the endogenous reference control
gene, GAPDH.
Statistical analysis
The significance of the association between specific histone 3.3 mutations and tumour type
was tested using one-sided Fisher exact tests.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Prevalence and distribution of histone 3.3 mutations in different tumour types
The percentage of cases in each series that harbour a specific histone 3.3 mutation is
indicated: paediatric glioblastoma multiforme4 (light blue); paediatric diffuse intrinsic
pontine glioma6 (dark blue); osteosarcoma (dark orange); giant cell tumour of bone (light
orange); clear cell chondrosarcoma (light green); conventional chondrosarcoma (white);
chondroblastoma (dark green). Circles represent amino acid residues which are identical for
H3F3A and H3F3B. Black circles represent post-translational modifications that occur at
residues: me = methylation; ac = acetylation; P = phosphorylation.
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Table 1
Genome wide somatic mutation burden of six chondroblastoma cases
For each tumour genome the absolute numbers of subs and indels are shown, along with histone 3.3 mutations.
Case PD7516a PD7517a PD7518a PD7520a PD7522a PD7523a
Substitutions 547 542 653 531 668 585
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Table 2
Histone 3.3 mutations in bone and cartilage tumours
Prevalence of histone 3.3 mutations identified in eight different tumour types are shown. K36M and G34W
mutations are mutually exclusive in chondroblastoma and giant cell tumour of bone (p<1×10−15). Amino acid




G34L G34R G34V G34W K36M G34R K36M
Chondroblastoma 77 73 (95%) 5 68
Giant cell tumour
of bone 53 49 (92%) 1 48
Clear cell
chondrosarcoma 15 1 (7%) 1
Osteosarcoma 103 2 (2%) 1 1
Conventional
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The mutant allele fraction in the stromal component of this tumour was low as it contained a large fraction of reactive fibroblasts.
Nat Genet. Author manuscript; available in PMC 2013 December 01.
